EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A Narrative Review on the FSTL-1 Protein and its Current Known Impact on Cardiovascular Ischaemic Disease

José Rodrigues Gomes

International Journal of Medical Students · 2024-12-17 · 12 (4) · 457-464

DOI: 10.5195/ijms.2024.2297 ↗
AbstractBibliografische Angaben

Abstract

This narrative review investigates the potential therapeutic role of FSTL-1 in addressing severe cardiac issues following myocardial infarctions (MI). Despite advances in modern medicine, MI persist as a leading global cause of death, with stem cell therapy falling short of expectations since the early 2000s. In contrast, FSTL-1, an emerging bone morphogenetic protein, demonstrates promise based on successful studies. We conducted a qualitative narrative synthesis of studies published in PubMed, Scopus, and Web of Science between January 2000 and May 2022. This research explores the intricate scientific aspects of FSTL-1's contribution to myocardial regeneration, utilizing a chronological approach to trace its progression from biological pathways to broader scenarios. It examines the mechanisms regulated by FSTL-1 and its effects on cardiac tissue and cells, highlighting its potential as a therapeutic agent emphasizing its multifaceted role in cardiac regeneration. By deepening our comprehension of FSTL-1, this study significantly contributes to knowledge advancement, offering insights into its role in addressing severe cardiac issues post-MI. By consolidating current knowledge and proposing new avenues for investigation, this work offers valuable insights into FSTL-1's significance in advancing cardiovascular health and post-MI recovery.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →